Work

Circulating tumor DNA–based clinical-genetic (CG) prognostic model for radiographic progression-free survival (rPFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Analysis of Alliance A031201.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.5018

Authors: Susan Halabi, Mengqi Xie, Chenxi Yu, Siyuan Guo, Hyotae Kim, Tianhao Song, Todd Knutson, Anna Kobilka, Jacqueline Lyman, Emmanuel S. Antonarakis, Himisha Beltran, Matthew D. Galsky, Jonathan E. Rosenberg, Charles J. Ryan, Eric J. Small, William Kevin Kelly, Michael J. Morris, David Page, Scott M. Dehm, Andrew J. Armstrong

Institutions: Duke University, Duke Medical Center, Duke Cancer Institute, University of Minnesota, Masonic Cancer Center, Dana-Farber Cancer Institute, Tisch Cancer Institute, Memorial Sloan Kettering Cancer Center, University of California, San Francisco, Thomas Jefferson University Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162542828

Cites:

Cited by: 1

Related to: